On Jun. 15, 2020, SIGA Technologies announced the U.S. Department of Defense (DoD) increased research and development funding to approximately $23 million in connection with the DoD contract to support work necessary to gain a potential label expansion from the FDA for TPOXX (tecovirimat) for Post-Exposure Prophylaxis in addition to the current approved labeling for the treatment of smallpox.